The Vitamin D for COVID-19 (VIVID) Trial: A Pragmatic Cluster-randomized Design

Overview

Journal Contemp Clin Trials

Publisher Elsevier

Date 2020 Oct 12

PMID 33045402

Citations 35

Authors

Rui Wang

Victor DeGruttola

Quanhong Lei

Kenneth H Mayer

Susan Redline

Aditi Hazra

Samia Mora

Walter C Willett

Davaasambuu Ganmaa

JoAnn E Manson

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the effect of vitamin D supplementation on disease progression and post-exposure prophylaxis for COVID-19 infection. We hypothesize that high-dose vitamin D3 supplementation will reduce risk of hospitalization/death among those with recently diagnosed COVID-19 infection and will reduce risk of COVID-19 infection among their close household contacts.

Methods: We report the rationale and design of a planned pragmatic, cluster randomized, double-blinded trial (N = 2700 in total nationwide), with 1500 newly diagnosed individuals with COVID-19 infection, together with up to one close household contact each (~1200 contacts), randomized to either vitamin D3 (loading dose, then 3200 IU/day) or placebo in a 1:1 ratio and a household cluster design. The study duration is 4 weeks. The primary outcome for newly diagnosed individuals is the occurrence of hospitalization and/or mortality. Key secondary outcomes include symptom severity scores among cases and changes in the infection (seroconversion) status for their close household contacts. Changes in vitamin D 25(OH)D levels will be assessed and their relation to study outcomes will be explored.

Conclusions: The proposed pragmatic trial will allow parallel testing of vitamin D3 supplementation for early treatment and post-exposure prophylaxis of COVID-19. The household cluster design provides a cost-efficient approach to testing an intervention for reducing rates of hospitalization and/or mortality in newly diagnosed cases and preventing infection among their close household contacts.

Citing Articles

Health Effects of Vitamin D Supplementation: Lessons Learned From Randomized Controlled Trials and Mendelian Randomization Studies.

Bouillon R, LeBoff M, Neale R J Bone Miner Res. 2023; 38(10):1391-1403.

PMID: 37483080 PMC: 10592274. DOI: 10.1002/jbmr.4888.

Does vitamin D reduce the mortality rate of Plasmodium infection?: a systematic review and meta-analysis.

Kalantari N, Sepidarkish M, Ghaffari S, Rostami-Mansoor S Malar J. 2023; 22(1):173.

PMID: 37277818 PMC: 10243038. DOI: 10.1186/s12936-023-04612-4.

Vitamin D, Menopausal Health and COVID-19: Critical Appraisal of Current Data.

Anagnostis P, Livadas S, Goulis D, Rees M, Lambrinoudaki I J Clin Med. 2023; 12(3).

PMID: 36769563 PMC: 9917790. DOI: 10.3390/jcm12030916.

Can vitamin D status influence seroconversion to SARS-COV2 vaccines?.

Shahini E, Pesce F, Argentiero A, Solimando A Front Immunol. 2023; 13:1038316.

PMID: 36601112 PMC: 9806423. DOI: 10.3389/fimmu.2022.1038316.

The relationship between vitamin D deficiency and mortality in older adults before and during COVID-19 pandemic.

Durmus M, Kara O, Kara M, Kaya T, Sener F, Durmus M Heart Lung. 2022; 57:117-123.

PMID: 36182862 PMC: 9482848. DOI: 10.1016/j.hrtlng.2022.09.007.

References

Laird E, Rhodes J, Kenny R . Vitamin D and Inflammation: Potential Implications for Severity of Covid-19. Ir Med J. 2020; 113(5):81. View

Greiller C, Suri R, Jolliffe D, Kebadze T, Hirsman A, Griffiths C . Vitamin D attenuates rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) and platelet-activating factor receptor (PAFR) in respiratory epithelial cells. J Steroid Biochem Mol Biol. 2018; 187:152-159. DOI: 10.1016/j.jsbmb.2018.11.013. View

Fauci A, Lane H, Redfield R . Covid-19 - Navigating the Uncharted. N Engl J Med. 2020; 382(13):1268-1269. PMC: 7121221. DOI: 10.1056/NEJMe2002387. View

Laaksi I, Ruohola J, Tuohimaa P, Auvinen A, Haataja R, Pihlajamaki H . An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr. 2007; 86(3):714-7. DOI: 10.1093/ajcn/86.3.714. View

Hansdottir S, Monick M, Lovan N, Powers L, Gerke A, Hunninghake G . Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. J Immunol. 2009; 184(2):965-74. PMC: 3035054. DOI: 10.4049/jimmunol.0902840. View

Gibney K, MacGregor L, Leder K, Torresi J, Marshall C, Ebeling P . Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis. 2008; 46(3):443-6. DOI: 10.1086/525268. View

Jing Q, Liu M, Zhang Z, Fang L, Yuan J, Zhang A . Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infect Dis. 2020; 20(10):1141-1150. PMC: 7529929. DOI: 10.1016/S1473-3099(20)30471-0. View

Hurwitz J, Jones B, Penkert R, Gansebom S, Sun Y, Tang L . Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection. J Pediatr. 2017; 187:323-327. PMC: 5588918. DOI: 10.1016/j.jpeds.2017.04.061. View

Martineau A, Jolliffe D, Hooper R, Greenberg L, Aloia J, Bergman P . Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017; 356:i6583. PMC: 5310969. DOI: 10.1136/bmj.i6583. View

10.

Zeger S, Liang K . Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121-30. View

11.

LeBlanc E, Perrin N, Johnson Jr J, Ballatore A, Hillier T . Over-the-counter and compounded vitamin D: is potency what we expect?. JAMA Intern Med. 2013; 173(7):585-6. DOI: 10.1001/jamainternmed.2013.3812. View

12.

Roth D, Shah R, Black R, Baqui A . Vitamin D status and acute lower respiratory infection in early childhood in Sylhet, Bangladesh. Acta Paediatr. 2009; 99(3):389-93. DOI: 10.1111/j.1651-2227.2009.01594.x. View

13.

Jeon S, Ko M, Lee J, Choi I, Byun S, Park S . Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrob Agents Chemother. 2020; 64(7). PMC: 7318052. DOI: 10.1128/AAC.00819-20. View

14.

Murdoch D, Slow S, Chambers S, Jennings L, Stewart A, Priest P . Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012; 308(13):1333-9. DOI: 10.1001/jama.2012.12505. View

15.

Leventis P, Kiely P . The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol. 2008; 38(2):149-53. DOI: 10.1080/03009740802419081. View

16.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

17.

Manson J, Bassuk S . Commentary. Eliminating vitamin D deficiency during the COVID-19 pandemic: A call to action. Metabolism. 2020; 112:154322. PMC: 7377789. DOI: 10.1016/j.metabol.2020.154322. View

18.

Greiller C, Martineau A . Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015; 7(6):4240-70. PMC: 4488782. DOI: 10.3390/nu7064240. View

19.

Gombart A, Pierre A, Maggini S . A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. Nutrients. 2020; 12(1). PMC: 7019735. DOI: 10.3390/nu12010236. View

20.

Mehta S, Giovannucci E, Mugusi F, Spiegelman D, Aboud S, Hertzmark E . Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010; 5(1):e8770. PMC: 2808247. DOI: 10.1371/journal.pone.0008770. View